| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acurx Pharmaceuticals, Inc. (ACXP) has 0 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. ACXP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | Scodari Joseph C | Director | Buy | 24,631 | $1.02 | $25,000.46 | +800.5% | -69.9% | -86.6% | |
| Jan 6, 2025 | Luci David P | President And CEO | Buy | 49,261 | $1.02 | $49,999.91 | +4.7% | -69.9% | -86.6% | |
| Jan 6, 2025 | Deluccia Robert J | Director, 10% Owner | Buy | 49,261 | $1.02 | $49,999.91 | +5.1% | -69.9% | -86.6% | |
| Jan 6, 2025 | Sailer Carl | Director | Buy | 24,631 | $1.02 | $25,000.46 | +21.9% | -69.9% | -86.6% | |
| Jan 6, 2025 | Dean Jack H | Director | Buy | 9,852 | $1.02 | $9,999.78 | +82.6% | -69.9% | -86.6% | |
| Jan 6, 2025 | Donohue James J. | Director | Buy | 9,852 | $1.02 | $9,999.78 | +78.8% | -69.9% | -86.6% | |
| Jul 27, 2022 | Sailer Carl | Director | Buy | 19,737 | $3.80 | $75,000.60 | +27.0% | -13.2% | -52.4% | |
| Jul 27, 2022 | Luci David P | President And CEO | Buy | 19,737 | $3.80 | $75,000.60 | +2.0% | -13.2% | -52.4% | |
| Jul 27, 2022 | Deluccia Robert J | Director, 10% Owner | Buy | 19,737 | $3.80 | $75,000.60 | +1.9% | -13.2% | -52.4% | |
| Nov 23, 2021 | Sailer Carl | Director | Buy | 5,161 | $4.84 | $24,979.24 | +7.6% | -14.2% | -37.1% |